The Effect of Melatonin on Benzodiazepine Discontinuation and Sleep Quality in Adults Attempting to Discontinue Benzodiazepines: A Systematic Review and Meta-Analysis
- 512 Downloads
Abrupt discontinuation of benzodiazepines often results in side effects including anxiety and insomnia, which can be barriers to discontinuation among long-term users. Melatonin improves the onset, duration, and quality of sleep. By preventing insomnia in those attempting to discontinue benzodiazepines, melatonin may facilitate benzodiazepine discontinuation.
The primary objective was to determine the effect of melatonin compared with placebo on benzodiazepine discontinuation in adults attempting to discontinue benzodiazepines. The secondary objective was to determine the effect of melatonin on sleep quality in this population.
We searched PubMed, MEDLINE, EMBASE, PsychINFO, and ClinicalTrials.gov from inception to November 2014. We included randomized controlled trials published in English comparing melatonin with placebo that reported benzodiazepine discontinuation or sleep quality. Two reviewers independently screened trials, extracted data, and assessed the risk of bias.
We included six trials randomizing 322 participants. The mean age of participants was approximately 64 years. The trials used varied tapering strategies to discontinue benzodiazepines over 4–10 weeks while using melatonin. Melatonin had no effect on the odds of successfully discontinuing benzodiazepines (odds ratio 0.72, 95 % confidence interval 0.21–2.41, p = 0.59). There was important heterogeneity among the trials (I2 = 76 %). The effect of melatonin on sleep quality was inconsistent.
Melatonin had no effect on benzodiazepine discontinuation while the effect of melatonin on sleep quality was inconsistent. We cannot rule out a role of melatonin in improving benzodiazepine discontinuation or sleep quality owing to imprecise effect estimates. Larger, well-designed, and reported randomized controlled trials may provide more valid and precise estimates of the effect of melatonin on these outcomes.
- 1.National Guideline Clearinghouse (NGC). Guideline summary: clinical practice guidelines for the management of patients with insomnia in primary care. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ) [cited 12 Nov 2014]. Available from: http://www.guideline.gov. Accessed 24 Oct 2015.
- 2.National Guideline Clearinghouse (NGC). Guideline summary: clinical guideline for the treatment of primary insomnia in middle-aged and older adults. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ) [cited 12 Nov 2014]. Available from: http://www.guideline.gov. Accessed 24 Oct 2015.
- 3.National Guideline Clearinghouse (NGC). Guideline summary: generalised anxiety disorder and panic disorder (with or without agoraphobia) in adult. Management in primary, secondary and community care. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); [cited 12 Nov 2014]. Available from: http://www.guideline.gov. Accessed 24 Oct 2015.
- 7.Billioti de Gage S, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, Pariente A, Bégaud B. Benzodiazepine use and risk of Alzheimer’s disease: case–control study. BMJ. 2014. doi:10.1136/bmj.g5205.
- 8.Billioti de Gage S, Bégaud B, Bazin F, Verdoux H, Dartigues, JF, Peres K, Kurth T, Pariente A. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012. doi:10.1136/bmj.e6231.
- 12.Oude Voshaar RC, Couvée JE, Van Balkom AJLM, Mulder PGH, Zitman FG. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. BJP. 2006;189:213–20.Google Scholar
- 15.Olde Rikkert MGM, Rigaud ASP. Melatonin in elderly patients with insomnia: a systematic review. Z Gerontol Geriat. 2001;34:491–7.Google Scholar
- 19.Siegrist C, Benedetti C, Orlando A, Beltran JM, Tuchscherr L, Noseda CMJ, Brusco LI, Cardinali DP. Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed middle-aged, and elderly patients. J Pineal Res. 2001;30:34–42.CrossRefPubMedGoogle Scholar
- 20.Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.1.0 [updated March 2011]. The Cochrane Collaboration, (2009). Available from: http://www.cochrane-handbook.org. Accessed 24 Oct 2015.
- 21.Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.Google Scholar
- 28.Baandrup L, Lindschou J, Winkel P, Gluud C, Glenthoj BY. Prolonged release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo-controlled, blinded trial. World J Biol Psychiatry. 2015. doi:10.3109/15622975.2015.1048725.
- 29.Voderholzer U, Riemann D, Hornyak M, Backhaus J, Feige B, Berger M, Hohagen F. A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. Eur Arch Psychiatry Clin Neurosci. 2001;251:117–23.CrossRefPubMedGoogle Scholar
- 30.Oude Voshaar RC, van Balkomb AJLM, Zitmanc FG. Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study. Eur Neuropsychopharmacol. 2004;14:301–6.Google Scholar